Iowa Medicaid Drug Utilization Review (DUR) Commission

March 3, 2021

Location: **Teleconference** (Due to COVID-19)
Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:
https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m02e3caff6409b4830333fd19ba29b770
Dial In: 1-844-245-7693
Meeting Number: 130 377 0514
Meeting Password: GFgGxNin328

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the Minutes
    b) November 2020 DUR Recommendation Letter to DHS
    c) November 2020 P&T Committee Recommendation Letter
    d) Follow-Up from Previous Meeting(s)
    e) Overview of Additions to SUPPORT Act Final Rule – see CMS-2482-F
3. IME Pharmacy Update
4. Prevalence Report Summaries
    a) Amerigroup
    b) Iowa Total Care
    c) Fee-for-Service
    d) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure.
    - Written - Must submit written comments and a completed conflict of interest disclosure.
    - Reference complete public comment policy here.
    - **All submissions must be received no later than 4:30 p.m. CT February 24, 2021.**
    - Send to info@iadur.org ***Indicate in email if providing written comment or verbal comment***.
6. Retrospective DUR
    a) Data Presentation(s)
        i. Concurrent Use of an SSRI and SNRI

ii. Duplicate Therapy – Two Unique Opioids
iii. Duplicate Therapy – Skeletal Muscle Relaxants
iv. Concurrent Gabapentinoid and Opioid
v. Concurrent Opioids and Benzodiazepines

b) Proposal(s)
i. Duplicate Therapy – Benzodiazepines
ii. Single Ingredient Buprenorphine

c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Break (10 minutes)
8. Prior Authorization
   a) Binge Eating Disorder – Initial Review
   b) IL-5 Antagonists – Initial Review
   c) Isotretinoin (Oral) – Initial Review
   d) Multiple Sclerosis Agents, Oral – Initial Review
   e) Nonsteroidal Anti-Inflammatory Drugs – Initial Review
   f) Proton Pump Inhibitors – Initial Review/Discussion
   g) Alpha$_2$ Agonists, Extended Release – Removal of Criteria – Initial Review
   h) Elagolix/Estradiol/Norethindrone Acetate (Oriahnn) – Second Review
   i) Select Anticonvulsants – Second Review
   j) Risdiplam (Evrysdi) – Second Review
   k) Satralizumab-mwge (Enspryng) – Second Review
9. Miscellaneous
   a) DUR Digest Vol. 33, No. 1 – Second Review
   b) MedWatch

   Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)
10. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

Next Meeting
May 5, 2021
Via Teleconference